Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 219 | 31 | 185 |
| Samples | 186 | 30 | 153 |
| Peptides | 140 | 17 | 127 |
Function
GOLGA6A · Golgin A6 family member A
The Golgi apparatus, which participates in glycosylation and transport of proteins and lipids in the secretory pathway, consists of a series of stacked cisternae (flattened membrane sacs). Interactions between the Golgi and microtubules are thought to be important for the reorganization of the Golgi after it fragments during mitosis. The protein encoded by this gene is a member of the golgin family of proteins, whose members localize to the Golgi. This gene is found in a large, low copy repeat sequence or duplicon that is found in multiple copies, that are greather than 90% similar, on chromosome 15. Duplicons are associated with deletions, inversions and other chromosome rearrangements that underlie genomic disease. The protein encoded by this gene is thought to be a functional golgin protein while the majority of the related copies of this gene are thought to be transcribed pseudogenes. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000290438 | Q9NYA3 | 219 | 140 |
Gene Properties
Recurrent Mutations
All 140 amino-acid changes on canonical ENST00000290438 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GOLGA6A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GOLGA6A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 10/612 2% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 18/1592 1% |
| Melanoma | 1/210 0% | 19/1899 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 11/1390 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 1/810 0% |
| Colorectal Carcinoma | 1/143 1% | 19/3239 1% |
| Other Solid Cancers | 1/94 1% | 8/1515 1% |
| Head and Neck Carcinoma | 2/85 2% | 7/1574 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Hepatocellular Carcinoma | 0/46 0% | 10/2210 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Gastric Carcinoma | 1/74 1% | 5/1809 0% |
| Other Blood Cancers | 0/61 0% | 8/2725 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Kidney Carcinoma | 0/85 0% | 5/1862 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Neuroblastoma | 3/87 3% | 0/1331 0% |
| Breast Carcinoma | 3/144 2% | 4/3264 0% |
| Bladder Carcinoma | 1/58 2% | 1/956 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| Pancreatic Carcinoma | 1/89 1% | 2/1611 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
Mutation Distribution
Where GOLGA6A is mutated · all tissues, split by cell line vs tissue
How many mutations in GOLGA6A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 45 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 219 mutations in GOLGA6A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|